作者: S. E. DePrimo , A. Cheng , S. Lanzalone , M. J. Lechuga , C. S. Harmon
DOI: 10.1200/JCO.2008.26.15_SUPPL.4593
关键词:
摘要: 4593 Background: Sunitinib malate (SU) is a multikinase inhibitor with antitumor activity in patients (pts) HCC (Faivre et al, ASCO 2007). To assess potential biomarkers of SU response, we inv...